XNAS
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -4.79 | -6.68 | -39.46% | $0 | ❌ Miss | +1.16% | +12.51% | — |
| 2026-05-13 | Q1 2026 | -7.32 | -8.94 | -22.13% | $0 | ❌ Miss | -1.76% | -10.49% | -9.83% |
| 2026-03-09 |
| Q4 2025 |
| -12.86 |
| -36.25 |
| -181.88% |
| $0 |
| ❌ Miss |
| +0.30% |
| -1.87% |
| +2.48% |
| 2025-11-10 | Q3 2025 | -15.56 | -14.58 | +6.30% | $0 | ✅ Beat | — | — | — |
| 2025-08-14 | Q2 2025 | -20.25 | -3.50 | +82.72% | $0 | mixed | — | — | +37.78% |
| 2025-04-15 | Q4 2024 | -0.20 | -0.57 | -185.00% | $697,000 | ❌ Miss | -6.82% | -1.82% | -50.08% |
| 2024-11-11 | Q3 2024 | -0.24 | -0.21 | +12.50% | $602,000 | ✅ Beat | -1.26% | -11.10% | -19.34% |
| 2024-08-12 | Q2 2024 | -0.30 | -0.22 | +26.67% | $1.6M | ✅ Beat | +3.88% | +12.52% | +12.52% |
Showing last 8 quarters.